Role of intranasal fentanyl in breakthrough pain management in cancer patients

Cancer Management and Research

Volumn 2, Issue 1, 2010, Pages 225-232

  Leppert, Wojciech ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Adverse effects; Analgesia; Breakthrough pain; Intranasal fentanyl; Opioid analgesics; Treatment

Indexed keywords

ANESTHETIC AGENT; CYTOCHROME P450 3A4; DECONGESTIVE AGENT; DRUG METABOLITE; FENTANYL; FENTANYL CITRATE; HYDROMORPHONE; KETAMINE; METHADONE; MORPHINE; NOSE SPRAY; OPIATE; OXYCODONE; PLACEBO;

ANALGESIA; ANXIETY; ARTERIAL OXYGEN SATURATION; BECK DEPRESSION INVENTORY; BLOOD BRAIN BARRIER; BONE PAIN; BREAKTHROUGH CANCER PAIN; CANCER PAIN; CHRONIC PAIN; CLINICAL CLASSIFICATION; CLINICAL TRIAL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DISEASE DURATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXCRETION; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG SOLUBILITY; DRUG TOLERABILITY; DRUG TOLERANCE; DYSPNEA; END OF DOSE PAIN; FIRST PASS EFFECT; HOME CARE; HUMAN; IDIOPATHIC PAIN; INCIDENT PAIN; MOOD DISORDER; NASAL PRURITUS; NAUSEA; NAUSEA AND VOMITING; NEUROPATHIC PAIN; NONINCIDENT PAIN; NOSE MUCOSA; PAIN ASSESSMENT; PATIENT CONTROLLED ANALGESIA; POSTOPERATIVE PAIN; PREVALENCE; QUALITY ADJUSTED LIFE YEAR; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TABLET; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSDERMAL PATCH; UNSPECIFIED SIDE EFFECT; VERTIGO;

EID: 78049380734     PISSN: None     EISSN: 11791322     Source Type: Book Series    
DOI: 10.2147/CMR.S7926     Document Type: Review

References (56)

1. Portenoy RK, Hagen NA. Breakthrough pain: Definition, prevalence and characteristics. Pain. 1990;41:273-281.
2. Hilgier M. Bole przebijajace w chorobie nowotworowej. Wspolcz Onkol. 2001;5:168-174.
3. Zeppetella G, O'Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage. 2000;20:87-92.
4. Gómez-Batiste X, Madrid F, Moreno F, et al. Breakthrough cancer pain: Prevalence and characteristics in patients in Catalonia, Spain. J Pain Symptom Manage. 2000;20:45-52.
5. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: Characteristics and impact in patients with cancer pain. Pain. 1999;81:129-134.
6. Caraceni A, Martini C, Zecca E, Portenoy RK; Working Group of an IASP Task Force on Cancer Pain. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med. 2004;18:177-183.
7. Mercadante S. Characteristics and mechanisms of BTCP. Eur J Palliat Care. 2010;17:8-12.
8. Davies AN. Assessment of BTCP. Eur J Palliat Care. 2010;17:13-15.
9. Foley KM. Acute and chronic cancer pain syndromes. In: Doyle D, Hanks G, Cherny N, Calman K, editors. Oxford Textbook of Palliative Medicine. Oxford: Oxford University Press; 2004.
10. Leppert W. Kliniczna ocena bolu w chorobie nowotworowej. Twoj Mag Med. 2005;5:34-40.
11. Mercadante S, Radbruch L, Caraceni A, et al; Steering Committee of the European Association for Palliative Care (EAPC) Research Network. Episodic (Breakthrough) Pain. Consensus Conference of an Expert Working Group of the European Association for Palliative Care. Cancer. 2002;94:832-839.
12. Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G. The management of cancer-related breakthrough pain: Recommendations of a Task Group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009;13: 331-338.
13. Hanks GW, de Conno F, Cherny N, et al; Expert Working Group of the Research Network of the European Association for Palliative Care. Morphine and alternative opioids in cancer pain: The EAPC recommendations. Br J Cancer. 2001;84:587-593.
14. Hui D, Bruera E. Breakthrough pain in cancer patients: The need for evidence. Eur J Palliat Care. 2010;17:58-67.
15. Zeppetella G. Opioids for cancer breakthrough pain: A pilot study reporting patient assessment of time to meaningful pain relief. J Pain Symptom Manage. 2008;35:563-567.
16. Mercadante S, Villari P, Ferrera P, Bianchi M, Casuccio A. Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio of with the oral daily morphine dose. J Pain Symptom Manage. 2004;27:352-359.
17. Enting R, Mucchiano C, Oldenmenger WH, et al. The "pain pen" for breakthrough cancer pain: A promising treatment. J Pain Symptom Manage. 2005;29:213-217.
18. de Conno, Ripamonti C, Saita L, et al. Role of rectal route in treating cancer pain: A randomized crossover trial of oral versus rectal morphine administration in opioid-naive cancer patients with pain. J Clin Oncol. 1995;13:1004-1008.
19. Hassenbusch SJ, Portenoy RK, Cousins M, et al. Polyanalgesic consensus conference 2003: An update on the management of pain by intraspinal drug delivery - report of an expert panel. J Pain Symptom Manage. 2004;27:540-563.
20. Davies AN, Vriens J, Kennett A, McTaggart M. An observational study of oncology patients' utilisation of breakthrough pain medication. J Pain Symptom Manage. 2008;35:406-411.
21. Portenoy RK. Adjuvant analgesic agents. Hematol Oncol Clin North Am. 1996;10:103-119.
22. Fulfaro F, Casuccio A, Ticozzi C, Ripamonti C. Pamidronate in incident pain due to bone metastases. J Pain Symptom Manage. 2001;22: 630-631.
23. Leppert W. The role of ketamine in the management of neuropathic cancer pain - a Polish experience. In: Wells CD, editor. Proceedings of the Third International Congress on Neuropathic Pain. Athens: Medimond International; 2010.
24. Mercadante S, Arcuri E, Ferrera P, Villari P, Mangione S. Alternative treatments of breakthrough pain in patients receiving spinal analgesics for pain. J Pain Symptom Manage. 2005;30:485-491.
25. Leppert W, Nowakowska E. Rola radioterapii w leczeniu objawow zaawansowanej choroby nowotworowej. Med Paliat Prakt. 2008;2: 33-47.
26. Burton AW, Reddy SK, Shah HN, Tremont-Lukats I, Mendel E. Percutaneous vertebroplasty - a technique to treat refractory spinal pain in the setting of advanced metastatic cancer: A case series. J Pain Symptom Manage. 2005;30:87-95.
27. Moser KM. Transdermal fentanyl in cancer pain. Am Fam Phys. 1992; 45:2289-2294.
28. Prommer E. The role of fentanyl in cancer-related pain. J Palliat Med. 2009;12:947-954.
29. Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: Preference, efficacy, and quality of life. J Pain Symptom Manage. 1997;13:254-261.
30. Leppert W, Luczak J, Gorzelinska L, Kozikowska J, Wozniak SP. The use of transdermal fentanyl (Durogesic) in the treatment of cancer pain. J Pain Symptom Manage. 2000;20:S79.
31. Gumulka WS. Narkotyczne leki przeciwbolowe. In: Gumulka W, Meszaros J, editors. Wspolczesne Metody Zwalczania Bolu. Warszawa: Osrodek Informacji Naukowej Polfa; 2000.
32. Zylicz Z, van Rijn-van der Plaat LL. Fentanyl may increase breathlessness in a patient with motor neuron disease. J Pain Symptom Manage. 2006;32:199-200.
33. Thomas JR, von Gunten CF. Management of dyspnoea. J Support Oncol. 2003;1:23-34.
34. Gauna AA, Kang SK, Triano ML, Swatko ER, Vanston VJ. Oral transmucosal fentanyl citrate for dyspnea in terminally ill patients: An observational study. J Palliat Med. 2008;11:643-648.
35. Sitte T. Nasal application of fentanyl citrate as symptom control against breathlessness in palliative care - overview and case report. Wien Med Wochenschr. 2009;159:566-570. German.
36. Zech DFJ, Lehmann KA, Grond S. Transdermal/TTS/fentanyl in cancer pain management. Progr Palliat Care. 1994;2:37-42.
37. Labroo RB, Paine MF, Thummel KE, Kharasch ED. Fentanyl metabolism by human hepatic and intestinal cytochrome P4503A4: Implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab Dispos. 1997;25:1072-1080.
38. Murtagh FE, Chai MO, Donohoe P, Edmonds PM, Higginson IJ. The use of opioid analgesia in end-stage renal disease patients managed without dialysis: Recommendations for practice. J Pain Palliat Care Pharmacother. 2007;21:5-16.
39. Dale O, Hjortkjaer R, Kharasch ED. Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand. 2002;46: 759-770.
40. Anonymous. Bol przebijajacy w chorobie nowotworowej. Niedoceniany problem. Nowa metoda leczenia. Instanyl - fentanyl aerozol donosowy. Warszawa: Nycomed Pharma; 2009.
41. Foster D, Upton R, Christrup L, et al. Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery. Ann Pharmacother. 2008;42:1380-1387.
42. Anonymous. Instanyl intranasal fentanyl spray. NYCOMED. Available at: www.instanyl.com. Accessed 2010 Jul 9.
43. Striebel HW, Kramer J, Luhmann I, Rohierse-Hohler I, Rieger A. Pharmakokinetische studie zur intranasalen gabe von fentanyl. Der Schmerz. 1993;7:122-125.
44. Kaasa S, Moksnes K, Nolte T, Lefebvre-Kuntz D, Popper L, Kress HG. Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain. J Opioid Manage. 2010;6:17-26.
45. Vissers D, Stam W, Nolte T, Lenre M, Jansen J. Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer. Curr Med Res Opin. 2010;26:1037-1045.
46. Striebel HW, Koenigs D, Krämer J. Postoperative pain management by intranasal demand-adapted fentanyl titration. Anesthesiology. 1992;77: 281-285.
47. Toussaint S, Maidl J, Schwagmaier R, Striebel HW. Patient-controlled intranasal analgesia: Effective alternative to intravenous PCA for postoperative pain relief. Can J Anesth. 2000;47:299-302.
48. Galinkin JL, Fazi LM, Cuy RM, et al. Use of intranasal fentanyl in children undergoing myringotomy and tube placement during halothane and sevoflurane anesthesia. Anesthesiology. 2000;93:1378-1383.
49. Manjushree R, Lahiri A, Ghosh BR, Laha A, Handa K. Intranasal fentanyl provides adequate postoperative analgesia in pediatric patients. Can J Anesth. 2002;49:190-193.
50. Zeppetella G. Nebulized and intranasal fentanyl in the management of cancer-related breakthrough pain. Palliat Med. 2000;14:57-58.
51. Zeppetella G. An assessment of the safety, efficacy, and acceptability of intranasal fentanyl citrate in the management of cancer-related breakthrough pain: A pilot study. J Pain Symptom Manage. 2000;20: 253-258.
52. Kress HG, Oronska A, Kaczmarek Z, Kaasa S, Colberg T, Nolte T. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 μg for breakthrough pain in patients with cancer: A Phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin Ther. 2009;31: 1177-1191.
53. Mercadante S, Radbruch L, Davies A, et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: An open-label, randomised, crossover trial. Curr Med Res Opin. 2009;25:2805-2815.
54. Stam W, Vissers D, Lenre M, et al. An economic evaluation of fastacting opioids for the treatment of breakthrough pain in cancer patients in Sweden. Eur J Pain. 2009;13 Suppl 1:S241.
55. Burkey A, Ballantyne J. The role of rapid-onset fentanyl in clinical practice. Eur J Palliat Care. 2010;17:88-90.
56. Carr DB, Goudas IC, Denman WT, et al. Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: A randomized, double-blind, placebo-controlled, crossover study. Pain. 2004;108:17-27.